拜瑞妥针对于房颤患者使用剂量是多少？拜瑞妥10mg房颤有效果吗？

Xarelto is a highly selective, oral drug that directly inhibits factor xa. Xarelto can interrupt the intrinsic and extrinsic pathways of the coagulation cascade by inhibiting factor xa, inhibiting thrombin generation and thrombosis. Xarelto is clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. What is the dosage of the oral drug Xarelto for patients with atrial fibrillation? Is 10 mg of atrial fibrillation effective?

Xarelto dosage for patients with atrial fibrillation

For use in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism: The recommended dose of Xarelto is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and advanced age (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

Xarelto treatment effects

Eisenberg MJ et al analyzed five randomized controlled studies (a total of 23,063 patients were included in the study, all of whom took Xarelto for ≥1 month, including 14,264 cases of non-valvular atrial fibrillation, 3,967 cases of deep vein thrombosis, and 3,967 cases of acute symptomatic pulmonary embolism). The results found that compared with vitamin K antagonists, Xarelto did not increase the composite endpoint of major bleeding and clinically relevant bleeding, and in the Xarelto group, fatal bleeding events were significantly reduced.

XANTUS is a real-world study showing the safety and effectiveness of Xarelto in a broader patient population than those included in the Phase III clinical trial, particularly in patients who still have anticoagulation requirements despite a low risk of blood clots. The XANTUS trial provides renewed reassurance for clinicians prescribing Xarelto, a drug that is effective and generally well tolerated in patients with atrial fibrillation at both high and low risk of stroke.

In the XANTUS trial, the average stroke risk was lower, with a CHADS2 score of 2.0. In the ROCKET AF study, the incidence of major bleeding in patients taking Xarelto was 3.6/100; in the XANTUS trial, the incidence of major bleeding in patients taking Xarelto was 2.1/100. In addition, a post-marketing safety surveillance study (PMSS study) involving 39,052 patients further confirmed the good safety profile of Xarelto, with the major bleeding incidence rate being 2.9/100.

The above is an introduction to Xarelto. If patients have other questions about the drug (such as drug prices, purchase channels, etc.), they can consult the medical companion travel service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related hot articles